EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Effect of Psychedelics on Individuals with a Personality Disorder: Results from Two Prospective Cohort Studies

Alexandra R. Gordon, Brennan M. Carrithers, Broc A. Pagni, Hannes Kettner, Alessia Marrocu MRes, Sandeep M. Nayak, Brandon M. Weiss, Robin L. Carhart-Harris, Daniel E. Roberts, David Erritzoe, Albert Garcia-Romeu, Heather Jackson, Matthew X. Lowe, Richard J. Zeifman

Psychedelic Medicine · 2026-12-01 · 4 (4) · 251-265

DOI: 10.1177/28314425251382930 ↗
AbstractBibliografische Angaben

Abstract

Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about the safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who self-reported a PD diagnosis. Methods: Study 1 included data from three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 involved a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (depressive symptoms, anxiety, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2–4 weeks, and 2–3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g = 0.52). There were several cases of clinically significant worsening of anxiety (Study 1: 0%; Study 2: 7.7 − 8.2%) and depression symptoms (Study 1: 0 − 7.1%; Study 2: 0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1: g = −0.46 to −0.57; Study 2: g = −0.52 to −0.89) and depression (Study 1: g = −0.54 to −0.59; Study 2: r s = 0.52–0.57). In Study 2, there were transient increases in cognitive flexibility at 2–4 weeks ( g = 0.26) and sustained increases in cognitive reappraisal up to 2–3 months ( g = 0.36). Increases in cognitive reappraisal were associated with reductions in anxiety ( r = −0.33) and depression ( r s = −0.37). Conclusion: Psychedelic use was on average associated with improvements in mental health outcomes for individuals who self-reported a PD diagnosis. There were no clinically significant post-psychedelic increases in SI, but there were a few cases of clinically significant increases in anxiety and depression severity. These preliminary findings are limited by the small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with a PD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →